BioMedNewsBreaks Archive - Page 77 of 269

WednesdaySep 25, 2024 11:10 am

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Newly Opened London-Based ACHIEVE UK Trial Site Amid ‘Very Positive’ Study Progression

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, is announcing Guys and St. Thomas Hospital, a London-based hospital with a leading oncology clinic and cell therapy clinical team, as a new site in the ACHIEVE UK Trial. The site opened in September 2024, expediting the progression of the trial timelines and increasing the velocity of enrollment. The ACHIEVE UK clinical trial is an open-label, Phase 2 study evaluating the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease. “The progression…

TuesdaySep 24, 2024 2:55 pm

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, will be presenting at the ThinkEquity Conference held on Oct. 30, 2024, in New York City. According to the announcement, TC Biopharm CEO Bryan Kobel will be presenting at the conference. During his presentation, Kobel will provide an overview of the company's clinical trials along with recent improvements to TC BioPharm's balance sheet. Hosted by ThinkEquity, a boutique investment bank, the ThinkEquity Conference is a premier showcase of private and public emerging growth companies from all over the world. To view the…

TuesdaySep 24, 2024 12:29 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Industry Expert, Pioneer as New Chief AI Scientist

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, has appointed a new chief artificial intelligence (“AI”) scientist: Lance Myers, PhD. According to the announcement, Myers is the former head of data science at Verily, formerly Google Life Sciences. A renowned industry leader and pioneer in digital health data analytics and body-worn biosensor technologies, Myers is a globally respected authority on utilizing AI in biosensor tech. In his new position, Myers will drive innovation and strategic growth for HeartBeam as the company looks to fully leverage its AI…

TuesdaySep 24, 2024 10:00 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more. To view the full press release, visit https://ibn.fm/3khUt About Nutriband Inc.…

MondaySep 23, 2024 11:20 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://ibn.fm/P0zd8 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

MondaySep 23, 2024 10:46 am

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Completes ACHIEVE Trial Full-Dose Regimen for First Patient

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has announced a key step in its ACHIEVE clinical trial. According to the announcement, the first patient has completed the full-dose regimen in the phase 2b trial. In addition, the company announced that six patients have received a second dose and three patients have received a third dose; patients can receive up to four total doses of TCB under the trial protocol. Furthermore, no TCB008-related adverse events have been observed in any of the restart patients. To view the full press release, visit…

FridaySep 20, 2024 2:30 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and prevents nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution…

FridaySep 20, 2024 12:45 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product

Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According…

ThursdaySep 19, 2024 11:25 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has been awarded a patent by the United States Patent and Trademark Office; the patent is titled “Formulations Comprising Triptan Compounds.” According to the announcement, the patent was issued on Sept. 17, 2024, and is slated to expire in 2030. The company noted that the patent claims a pharmaceutical composition, a method of treating migraine via intranasal administration and an intranasal delivery system for Tosymra(R). “We believe this patent further solidifies Tosymrain the market as a differentiated drug with a differentiated administration…

ThursdaySep 19, 2024 11:10 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Expansion of Its Telehealth Services Nationwide, New Service

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced a partnership with Lyric Health, a comprehensive virtual care provider. This partnership, which entails integrating HealthLynked with Lyric Health, enables the company to expand its telehealth services nationwide to all 50 states. As part of this expansion, the company has introduced its new Virtual Urgent Care service, which enables members to connect with a licensed physician within an average of 20 minutes. Additionally, HealthLynked intends to launch its Virtual Primary Care service, which will allow users to set future appointments with primary care physicians, establishing ongoing relationships with virtual doctors.…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Newly Opened London-Based ACHIEVE UK Trial Site Amid ‘Very Positive’ Study Progression

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Industry Expert, Pioneer as New Chief AI Scientist

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Completes ACHIEVE Trial Full-Dose Regimen for First Patient

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Expansion of Its Telehealth Services Nationwide, New Service

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search